Sirius Therapeutics Raises $50Million for siRNA Drug Development

Sirius Therapeutics announced that it has successfully completed nearly $50 million Series B2 financing to advance clinical development of the Company’s novel siRNA therapeutics for cardiometabolic disorders and continued innovation of its next-generation RNA delivery technologies. A renowned corporate venture capital firm led the financing round that was joined by a new investor, BioTrack Capital, and existing investors OrbiMed, Creacion Ventures, and Hankang Capital.

Health Technology Insights: EmmiTec.Health Announces It Has Joined the PointClickCare Marketplace

“The successful completion of our Series B2 financing is a strong endorsement of our progress to date and our strategy going forward,” said Dr. Qunsheng Ji, CEO of Sirius Therapeutics. “We are deeply grateful to our new and existing investors for their continued support. The funds from this round will further advance our clinical programs and expand our pipeline, to deliver “transformative siRNA therapeutics for patients with chronic diseases” around the world.”

Health Technology Insights: COPILOT Appoints Era Prakash as Senior Vice President of Solutions Development

Dr. Ji noted that the company has three clinical-stage programs and a deep preclinical pipeline. The most advanced compound, SRSD107, is a long-acting, next-generation anticoagulant for thromboembolic disorders poised to begin Phase 2 clinical development in Europe. The company recently applied to the European Medicines Agency (EMA) to initiate a Phase II trial. Sirius has also received approvals from the U.S. FDA and the China NMPA and has begun Phase 1 studies with SRSD216, a novel siRNA therapeutic for hyperlipoproteinemia in patients with atherosclerotic cardiovascular disease. SRSD101, the company’s siRNA therapeutic for dyslipidemia, is undergoing Phase 1 clinical trials in China.

Health Technology Insights: Doktorconnect Acquires VitalFlo to Integrate Proactive Respiratory Care Solutions

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire

Tags: $50 Million, Cardiometabolic Diseases, Clinical Development, healthcare, Sirius Therapeutics, siRNA Therapeutics

HealthTech Media Room

HealthTech Media Room is a leading B2B media publication platform providing in-depth coverage of the rapidly evolving healthcare technology and academic research sectors. Specializing in key focus areas such as MedTech, Pharma, Digital Health, Health IT, and Biotech, HealthTech Media Room delivers the latest news, trends, and insights across the entire HealthTech landscape. From breakthrough medical devices and innovative pharmaceuticals to cutting-edge digital health solutions, the platform highlights key players, strategic partnerships, and transformative technologies shaping the future of healthcare. Serving as a trusted resource for industry professionals, thought leaders, and healthcare organizations, HealthTech Media Room is dedicated to driving conversations and knowledge sharing in the global HealthTech community.